Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R, S)-(±)-Sodium Ibuprofen Dihydrate - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R, S)-(±)-Sodium Ibuprofen Dihydrate
The racemic compound (R, S)-()-ibuprofen is a popular and well understood active pharmaceutical ingredient, but it has several disadvantageous formulation properties such as poor solubility, low melting point, and potential esterification with excipients containing an hydroxyl group. The authors investigate the use of an (R, S)-()-ibuprofen salt to evaluate these problems using various analytical methods to determine the polymorphism, crystallinity, and drying scheme.

Pharmaceutical Technology

Table II: Total Hildebrand values for solvents at 25 8C versus enthalpies and entropies of solution of (R, S)-(6)-sodium ibuprofen dihydrate.
The values of (ΔHd) and (ΔSd) for (R, S)-()-sodium ibuprofen dihydrate are summarized in Table II for qualitative comparisons. The positive values of ΔHd in Table II indicate that the energy of attraction of (R, S)-()-sodium ibuprofen dihydrate with each other, and the energy of attraction of the solvent molecules with each other were lower than the energy of attraction of (R, S)-()-sodium ibuprofen dihydrate and the solvent molecules in the solution. Heat was absorbed to make (R, S)-()-sodium ibuprofen dihydrate dissolve in the solvent. The solubility of (R, S)-()-sodium ibuprofen dihydrate increased with temperature. The positive values of (ΔSd) in Table II show that (R, S)-()-sodium ibuprofen dihydrate-solvent systems became less ordered as (R, S)-()-sodium ibuprofen dihydrate dissolved into the solution. The entropy gain of the whole system was the main driving force for dissolution.

Table III. Solvent miscibility table, cosolvent, and antisolvent systems of (R,S)-(6)-sodium ibuprofen dihydrate.
Because of the symmetrical nature of the solvent miscibility table (see Table III), the number of boxes was divided by 2, except for the diagonal boxes (13). Based on the solvent miscibility studies of the solvent pairs of the 23 solvents, 36 gray boxes were divided by 2 to give 18 immiscible pairs in total (see Table III). The form space (i.e,. a possible location for discovering a new polymorph) of the pure-solvent systems for the initial solvent-screening was limited to the number of good pure solvents (repesented by the yellow boxes). The form space for (R, S)-()-sodium ibuprofen dihydrate was 9. However, if the good cosolvent systems (i.e., binary miscible mixtures of good solvents) were taken into account, the form space would be extended to the total number of blue boxes in the solvent miscibility table divided by 2 (see Table III), which was equal to 36. In addition, if the antisolvent systems (i.e., binary miscible mixtures of a good and a bad solvent) also were considered, the form space of the antisolvent systems was calculated as the number of green boxes in the solvent miscibility table divided by 2 (see Table III); this value was 109.

Consequently, the total form space should then be at least equal to 9 + 36 + 109 =154. The total form space is expected to expand dramatically if various solvent compositions of binary mixtures, temperatures, and ternary solvent systems also are considered. Solid generation by temperature cooling only was applied in the yellow regions, yet the same crystallization mode could be applied to the blue regions in the solvent-miscibility table (see Table III). For the green regions (see Table III), solid generation is achieved isothermally by adding an antisolvent. Generally, no attempts are made for solid generation in the regions of immiscible solvent pairs (represented by the purple boxes), bad solvents (represented by the red boxes), and cosolvents of bad solvents (i.e., binary mixture of miscible bad solvents) (represented by the white boxes) in the solvent miscibility table (see Table III). References of other miscible solvents pairs from organic solvents other than the 23 solvents listed in Table III are available in the literature (19, 20).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here